Current Approaches to Surgical Antimicrobial Prophylaxis and Use of Antimicrobial Prophylaxis in Urological Procedures

Cerrahi Öncesi Profilaksi Profilaktide Güncel Yaklaşımlar Işığında Ürolojik Preoperatif Antibiyotik Uygulamaları

Pınar Şen, Tuna Demirdal
İzmir Katip Çelebi University, Atatürk Training and Research Hospital, Department of Infectious Disease and Clinical Microbiology, İzmir, Türkiye

Abstract

Surgical site infections (SSIs) are the most common and preventable type of healthcare-associated infections in low and middle-income countries and affect one-third of patients that have undergone surgical procedures. As the number of surgical procedures performed increases, the prevention of SSIs becomes more important. It is considered that, it is possible to prevent approximately half of all SSI cases. However, due to the contribution of many factors to the development of SSIs, it may be difficult to effectively prevent these infections, and there is a need to take various preventive measures before, during and after surgery. This review presents the current recommendations on the use of prophylactic antimicrobial agents for the prevention of SSIs and recommendations about antimicrobial prophylaxis in urological procedures.

Keywords: Surgical site infections, antibiotics, prophylaxis

Introduction

Healthcare-associated infections are the most important adverse events that affect patient safety across the globe (1). The World Health Organization (WHO) has reported that surgical site infections (SSIs) are the most common and preventable type of healthcare-associated infections in low- and middle-income countries and affect one-third of patients that have undergone surgical procedures (1,2). According to the Ministry of Health in Turkey, SSIs are the third most common healthcare infections in the country, accounting for approximately 20% of all infections (2). In Turkey, the incidence of SSIs after surgery has been reported to be 1% by the National Hospital Infection Control Unit whereas it is 1.9% in the United States (1,3,4,5).

As the number of surgical procedures performed increases, the prevention of SSIs becomes more important (6). It is considered that by using evidence-based strategies, it is possible to prevent approximately half of all SSI cases (7). However, due to the contribution of many factors to the development of SSIs (8), it may be difficult to effectively prevent these infections, and there is a need to take various preventive measures before,
during and after surgery. Improving surgical techniques and ventilation in the operating room, sterilization, barrier precautions, and antibiotic prophylaxis are among the main measures for preventing SSI-related morbidity and mortality (8,9). Thus, surgeons, infectious disease specialists and healthcare workers play a major role in protecting patients from SSIs (2). This review presents the current recommendations on the use of prophylactic antimicrobial agents for the prevention of SSIs, provided by various guidelines [WHO, Centers for Disease Control and Prevention (CDC), American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Surgical Infection Society, the Society for Healthcare Epidemiology of America and the European Association of Urology (EAU)].

**Definition of Surgical Site Infections**

Different definitions have been made in relation to SSIs, however, all sources agree that there is no single objective gold standard test for these infections (10). According to the definition provided by CDC, SSI is a post-operative infection that occurs at the site of incision, in the organ or at the surgical site (10). Based on this definition, SSIs are divided into the following three classes; superficial incisional, deep incisional, and organ/space (11). Superficial and deep incisional SSIs are further classified as primary or secondary according to the infection being identified in the first incisional line or second incisional line in the presence of multiple incisions, respectively (8,11). Taking the day of surgery as the first day, superficial incisional SSIs are defined as the presence of infections in the skin and subcutaneous tissue that develop within the first 30 days of procedures performed with an incision (8,11). Deep incisional SSIs are infections that develop in the deep tissue incision, such as the muscle or fascia within 30 or 90 days of surgery, and lastly, organ/space SSIs are those that involve any body region deeper than the muscle/fascia layer and develop within 30 or 90 days of surgical intervention (11). Table 1 shows the types of surgery in which 30-day and 90-day surveillance for SSIs are undertaken.

The degree of wound contamination is one of the most important factors in the development of SSIs (12). Surgical wounds are divided into the four classes of clean, clean-contaminated, contaminated, and dirty-infected (2). According to the US National Nosocomial Infections Surveillance (NNIS) system, the rate of infection is 1-3% in clean wounds, 3-10% in clean-contaminated wounds, 5-15% in contaminated wounds, and 7% in dirty-infected wounds (12).

**Causative Microorganisms**

The main source of SSI-causative microorganisms is endogenous fluoride from the mucous membranes, skin and intestinal system (9). The most determinative factor in determining the agents to be used in antibiotic prophylaxis is the identification of microorganisms and resistance patterns that are most often the agents of SSIs. The presence of more comorbid diseases in surgical patients in recent years and the emergence of pathogens resistant to antimicrobial agents lead to additional cost and
Surgical Site Infection Risk Factors

There are many factors that affect surgical wound healing and the possibility of infection (16), including patient-related (endogenous) and procedure-related (exogenous) variables (1). Some factors, such as patient age and gender are fixed but other potential variables, e.g., nutritional status, smoking, rational antibiotic use, compliance with asepsis-antisepsis techniques, technical conditions of the operating room, and intraoperative techniques, can be improved to provide positive surgical outcomes (1,16). A systematic review of 57 studies conducted in various countries showed that a high body mass index, severe wound class, diabetes, and a high NNIS risk index were associated with increased SSIs (17). The NNIS index is a classification developed by the CDC to identify risk of SSIs after surgery and compare the infection rates between surgical patients (18). This scoring system is based on different variables, such as the physical status score in the scale developed by the American Society of Anesthesiologists and the duration of operation (18). Other risk factors include increased prevalence of resistant microorganisms, increased number of patients with comorbidities and immunosuppression due to the prolonged life span, and the increasing number of surgical interventions undertaken for these patients (e.g., prosthetic applications and organ transplantation) (8), as well as non-compliance with surgical asepsis and inappropriate use of antibiotics (8,19).

Recommendation Categories

Recommendations regarding the prevention of SSIs have been grouped into the following categories based on a standard system reflecting the level of supporting evidence and regulations (20):

• **Category IA:** A strong recommendation supported by high to moderate quality evidence suggesting net clinical benefits or harms.

• **Category IB:** A strong recommendation supported by low quality evidence suggesting net clinical benefits or harms or an accepted practice (e.g., aseptic technique) supported by low to very low-quality evidence.

• **Category IC:** A strong recommendation required by state or federal regulation.

• **Category II:** A weak recommendation supported by any quality evidence suggesting a trade-off between clinical benefits and harms.

• **No recommendation/unresolved issue:** An issue for which there is low to very low-quality evidence with uncertain trade-offs between the benefits and harms or no published evidence on outcomes deemed critical to weighing the risks and benefits of a given intervention.

Current Recommendations

**Parenteral Antimicrobial Prophylaxis**

Preoperative antimicrobial agents should only be administered in the presence of indications based on published clinical practice guidelines and in cases where sufficient bactericidal concentrations of serum and tissue are achieved with incision (category IB) (Table 2) (20,21,22). The 1999 CDC guidelines and other clinical practice guidelines for the prevention of SSIs recommend a single intravenous dose of prophylactic antibiotic only when it is indicated as appropriate (16). For most prophylactic agents, the 1999 CDC guidelines recommend the administration of antimicrobial prophylaxis 60 minutes before incision, but for vancomycin and fluoroquinolones, this should be administered 60 to 120 minutes before incision (1,16,21). However, there is no clear data concerning the need for complete or partial infusion of the parenteral antibiotic dose prior to surgical incision (20).

Preoperative antimicrobial agents should not be administered based on clinical outcomes (in cases of no recommendation/unresolved issue) (20).

In all cesarean procedures, an appropriate parenteral prophylactic antimicrobial agent should be administered before skin incision (category IA) (20). Clinical practice guidelines suggest using prophylactic antibiotics 60 minutes prior to skin incision in both elective and emergency cesarean sections (21,22,23). Antimicrobial prophylaxis is no longer recommended after cord clamping (16).

In clean and clean-contaminated procedures, no additional prophylactic antimicrobial agents should be administered after the closure of surgical incision even in the presence of a drain (category IA) (20).

A review of the literature shows the lack of randomized controlled trials evaluating the benefits and ill effects of weight-adjusted parenteral antimicrobial prophylaxis and their impact on SSI risk (no recommendation/unresolved issue) (20). However, recommendations have been made based on observational and pharmacokinetic data (20). Clinical practice guidelines suggest increasing the dose of single-dose prophylactic antimicrobial...
agent to be used in obese and morbidly obese patients (21,22,23,24). For example, for cefazolin, >2 g is recommended for patients weighing 60-80 kg and 3 g for patients >120 kg (21,23,25). The appropriate dose for aminoglycosides should be calculated by adding 40% of the difference between the actual and ideal body weights of patients to their ideal body weight (21,24,26). For vancomycin, the recommended dose is 15 mg/ kg (25).

There are only a limited number of randomized controlled trials that have investigated the benefits and ill effects of a repeated intraoperative dose of parenteral prophylactic antibiotics to prevent SSI (no recommendation/unresolved issue) (20). However, suggestions have been made based on observational and pharmacokinetic data (20). Clinical practice guidelines indicate that prophylactic antimicrobial agents should be repeated in cases of prolonged treatment (when the duration of the surgical procedure exceeds the prophylactic half-life of the antibiotic or is longer than 3-4 hours), blood loss of more than 1500 mL, and widespread burns (21,24,25,27).

A wide-scale meta-analysis of the efficacy and optimal application duration of postoperative antimicrobial prophylaxis demonstrated high quality evidence that there was no benefit in continuing antimicrobial prophylaxis after the closure of surgical incisions (28,29,30). A meta-analysis of three randomized controlled trials in cardiovascular surgery showed moderate quality evidence that the continuation of antimicrobial prophylaxis did not provide any additional benefits after intraoperative closure of surgical incision (28,31,32).

Table 2. Suggested empiric antibiotics by surgical procedure (21,22)

<table>
<thead>
<tr>
<th>Surgery</th>
<th>Suggested antibiotics</th>
<th>ß-lactam allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac/vascular/thoracic surgery</td>
<td>Cefazolin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Cardiac surgery with prosthetic material</td>
<td>Cefazolin + vancomycin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Cardiac device insertion (pacemaker implantation)</td>
<td>Cefazolin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Gastrointestinal surgery</td>
<td>Cefazolin</td>
<td>Vancomycin¹ + gentamicin</td>
</tr>
<tr>
<td>Biliary tract surgery</td>
<td>Cefazolin</td>
<td>Metronidazole + levofloxacin</td>
</tr>
<tr>
<td>Colorectal surgery, appendectomy</td>
<td>Cefazolin + metronidazole</td>
<td>Metronidazole + levofloxacin</td>
</tr>
<tr>
<td>Other general surgery (hernia repair, breast)</td>
<td>Cefazolin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Gynecological (hysterectomy), cesarean delivery</td>
<td>Cefazolin</td>
<td>Clindamycin¹ + gentamicin</td>
</tr>
<tr>
<td>Head and neck surgery</td>
<td>Clean: Cefazolin</td>
<td>Clindamycin</td>
</tr>
<tr>
<td></td>
<td>Clean-contaminated:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ear/sinonasal procedure: Cefazolin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Oral mucosal procedure: Cefazolin + metronidazole</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contaminated: Cefazolin + metronidazole</td>
<td></td>
</tr>
<tr>
<td>Neurosurgery</td>
<td>Cefazolin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Orthopedic surgery</td>
<td>Cefazolin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Plastic surgery</td>
<td>Cefazolin</td>
<td>Vancomycin¹</td>
</tr>
<tr>
<td>Urological surgery²</td>
<td>Cefazolin</td>
<td>Clindamycin² + gentamicin²</td>
</tr>
<tr>
<td></td>
<td>Open/laparoscopic surgery: (clean) (skin incision, does not involve genitourinary tract)</td>
<td>Clindamycin²a</td>
</tr>
<tr>
<td></td>
<td>Open/laparoscopic surgery involving intestine: (clean-contaminated) (radical cystectomy + ileal conduit)</td>
<td>Metronidazole + levofloxacin</td>
</tr>
<tr>
<td></td>
<td>Cefoxitin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If prosthetic material involved in urologic procedures, should add one-time dose of gentamicin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If prosthetic material involved in urologic procedures, should add one-time dose of gentamicin if not already given</td>
<td></td>
</tr>
</tbody>
</table>

¹Clindamycin can be used as an alternative to vancomycin. Clindamycin and vancomycin are recommended alternative agents to cefazolin for patients with beta-lactam allergies.
²Urology notes. ²²If significant concern for methicillin-resistant Staphylococcus aureus, vancomycin should be considered as an alternative to clindamycin. ²²Ciprofloxacin is a reasonable alternative. However, according to the 2015 SHC antibiogram, more Escherichia coli isolates were susceptible to aminoglycosides than fluoroquinolones (http://lane.stanford.edu/biomed-resources/antibiograms-shc.html)
• Non-parenteral Antimicrobial Prophylaxis

The existing randomized controlled trials present contradictory data concerning the benefits and ill effects of intraoperative antimicrobial irrigation (e.g., intra-abdominal, deep or subcutaneous tissues) in preventing SSIs (no recommendation/unresolved issue) (20). Two clinical practice guidelines based on reviewing evidence suggest using antimicrobial wound irrigation or intracavity lavage to reduce the risk of SSI (1,27). There is no randomized controlled study that evaluated soaking prosthetic devices in antimicrobial solutions before implantation for the prevention of SSIs (no recommendation/unresolved issue) (20).

Antimicrobial agents (e.g., ointments, solutions or powders) should not be applied to surgical incision to prevent SSIs (category IB) (20). However, clinical practice guidelines have different approaches concerning the recommendation of the application of non-parenteral antimicrobials to surgical incision in the absence of SSIs (27,33).

Autologous platelet-rich plasma transfusion (spray or gel) is not considered necessary for the prevention of SSIs (category II) (20). The use of triclosan-coated sutures should be considered for preventing SSIs (category II) (20).

In randomized controlled trials in the literature, it has been suggested that there was uncertainty regarding the benefits and ill effects associated with antimicrobial dressings applied to surgical incisions following primary closure in the operating room (no recommendation/unresolved issue) (20).

Current Recommendations on Prophylaxis in Urological Surgery

EAU Panel of Urological Infection Guidelines consists of a group of urologists with expertise in this field and in infectious diseases. These Urological Infection Guidelines, first published in 2001 and revised in 2017, state that the infection risk varies according to the type of intervention, and there are no clear instructions concerning antimicrobial prophylaxis due to the wide variety of the intervention types and the recent developments in minimally invasive surgery; thus, these guidelines propose evaluating the requirements of each case individually to make a decision about prophylaxis (34). Furthermore, according to the EAU guidelines, when selecting antimicrobial agents, the role of local pathogen profiles, pathogen susceptibility and virulence, procedure-specific risk factors, contamination load, target organ and local inflammation should be taken into consideration (34). Table 3 presents the recommendations on antimicrobial prophylaxis according to surgical procedure. In cases where antimicrobial prophylaxis is indicated, fluoroquinolones, trimethoprim ± sulfamethoxazole, aminopenicillin/beta-lactamase inhibitor, second- or third-generation cephalosporin, or even piperacillin/tazobactam are among the recommended agents.

Prophylaxis in Diagnosis

• Cystoscopy

The frequency of infectious complications reported after cystoscopy, standard urodynamic investigation and ureteroscopy is very low if the urine is sterile in the preoperative period (35). Routine antimicrobial prophylaxis is not recommended due to the frequency of diagnostic cystoscopy, low risk of infection, and developing bacterial resistance (34). However, bacteriuria, permanent catheterization, neurogenic lower urinary tract disease, and urogenital infection history are among the risk factors that should be considered (36).

• Transrectal Prostate Biopsy

It has been found that administration of antimicrobial prophylaxis in transrectal prostate biopsy significantly reduces the risk of infection after the procedure (37); therefore, antimicrobial prophylaxis is recommended after transrectal biopsy (34). Although fluoroquinolones are the most frequently used agents in prophylaxis, the duration of prophylaxis and the choice of antibiotics should be discussed first (34). It has also been reported that the use of fosfomycin trometamol or prophylactic antimicrobial based on rectal swab is currently being investigated as an alternative to antimicrobial prophylactic agents, meta-analyses are being undertaken, and new recommendations on prophylaxis will be included in guidelines to be published in the following years (38,39,40).

Prophylaxis in Endourological Treatment Procedures (Urinary Tract Entered)

• Transurethral Resection of the Bladder

There is limited evidence of the benefit of antimicrobial prophylaxis before transurethral resection of the bladder (34). In studies on the benefits of prophylaxis, no distinction has been made concerning simple fulguration, large or multiple tumors, or presence of necrotic material. Therefore, the present guidelines recommend the selection of appropriate prophylaxis depending on the tumor differentiation.

• Transurethral Resection of the Prostate

According to the results of a considerable number of studies undertaken on this procedure, antimicrobial prophylaxis
significantly reduces bacteriuria and septicemia, and prophylactic agents before transurethral resection of the prostate is recommended (35).

- **Ureteroscopy**

  There are no prospective controlled studies evaluating the use of prophylactic agents in ureteroscopy (34). The current guidelines state that a differentiation should be made between diagnoses in healthy individuals pertaining to low-risk procedures, such as treatment of distal ureteral stones and high-risk procedures; e.g., treatment of obstructing proximal stones. Therefore, it is advisable to take the decision concerning prophylactics based on patient-related risk factors (41).

- **Percutaneous Nephrolithotripsy**

  It has been shown that the infection risk is high in percutaneous nephrolithotripsy and retrograde intrarenal stone treatment, and prophylactic antibiotics significantly reduce the risk of infectious complications (41,42). It has been noted that in these cases, a single dose of prophylactic antibiotics is sufficient (43).

- **Extracorporeal Shock Wave Lithotripsy**

  Antimicrobial prophylaxis is not recommended as a standard application in extracorporeal shock wave lithotripsy (35). However, it is indicated to use prophylaxis for the control of bacteriuria and in elevated bacterial load, such as permanent catheter, nephrostomy tube, or presence of infective stones (44).

- **Laparoscopic Surgery**

  Although there are not an adequate number of studies on antimicrobial prophylaxis in laparoscopic surgery, it seems reasonable to follow the recommendations provided for open surgical interventions (34).

- **Nephrectomy, Adrenalectomy**

  Although antimicrobial prophylaxis is not recommended as standard, it has been reported that in some cases, its use can be assessed at the discretion of the surgeon (45).

- **Prostatectomy**

  Antimicrobial prophylaxis is recommended in open enucleation of prostate adenoma due to the high risk of postoperative...

---

Table 3. Recommendations for prophylactic agent in urological surgery (33)

<table>
<thead>
<tr>
<th>Surgical procedure</th>
<th>Antimicrobial prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic procedures</td>
<td>-</td>
</tr>
<tr>
<td>Cystoscopy</td>
<td>Fluoroquinolones</td>
</tr>
<tr>
<td>Urodynamic study</td>
<td>Trimethoprim ± sulphamethoxazole</td>
</tr>
<tr>
<td>Transrectal core biopsy of prostate</td>
<td>Optional</td>
</tr>
<tr>
<td>Diagnostic ureteroscopy</td>
<td>Optional</td>
</tr>
<tr>
<td>Endourological/endoscopic therapeutic procedures</td>
<td>Optional</td>
</tr>
<tr>
<td>Fulguration of small baldder tumours</td>
<td>Trimethoprim ± sulphamethoxazole</td>
</tr>
<tr>
<td>Transurethral resection of the bladder</td>
<td>Aminopenicillin / beta-lactamase inhibitor</td>
</tr>
<tr>
<td>Transurethral resection of the prostate</td>
<td>Cephalosporin (2 or 3. group)</td>
</tr>
<tr>
<td>Shock-wave lithotripsy</td>
<td></td>
</tr>
<tr>
<td>Ureteroscopy for stone management</td>
<td></td>
</tr>
<tr>
<td>Percutaneous and retrograde intrarenal stone management</td>
<td></td>
</tr>
<tr>
<td>Open and/or laparoscopic surgery</td>
<td>-</td>
</tr>
<tr>
<td>Nephrectomy ± ureterectomy</td>
<td>Aminopenicillin/beta-lactamase inhibitor</td>
</tr>
<tr>
<td>Adrenalectomy</td>
<td>Piperazillin/tazobactam</td>
</tr>
<tr>
<td>Radical prostatectomy</td>
<td>Optional</td>
</tr>
<tr>
<td>Planned scrotal surgery, vasectomy, varicoce surgery</td>
<td>Cefuroxim</td>
</tr>
<tr>
<td>Prosthetic implants</td>
<td>Aminopenicillin/beta-lactamase inhibitor + metronidazole</td>
</tr>
<tr>
<td>Artificial sphincter</td>
<td></td>
</tr>
<tr>
<td>Ureteropelvic junction repair</td>
<td></td>
</tr>
<tr>
<td>Partial bladder resection</td>
<td></td>
</tr>
<tr>
<td>Cystectomy with urine deviation</td>
<td></td>
</tr>
</tbody>
</table>

- **Diagnostic procedures**

  - Cystoscopy
  - Urodynamic study
  - Transrectal core biopsy of prostate

- **Diagnostic ureteroscopy**

  Endourological/endoscopic therapeutic procedures

  - Fulguration of small baldder tumours
  - Transurethral resection of the bladder
  - Transurethral resection of the prostate
  - Shock-wave lithotripsy

- **Diagnostic procedures**

  - Ureteroscopy
  - Endourological/endoscopic therapeutic procedures

- **Ureteroscopy**

  There are no prospective controlled studies evaluating the use of prophylactic agents in ureteroscopy (34). The current guidelines state that a differentiation should be made between diagnoses in healthy individuals pertaining to low-risk procedures, such as treatment of distal ureteral stones and high-risk procedures; e.g., treatment of obstructing proximal stones. Therefore, it is advisable to take the decision concerning prophylactics based on patient-related risk factors (41).

- **Percutaneous Nephrolithotripsy**

  It has been shown that the infection risk is high in percutaneous nephrolithotripsy and retrograde intrarenal stone treatment, and prophylactic antibiotics significantly reduce the risk of infectious complications (41,42). It has been noted that in these cases, a single dose of prophylactic antibiotics is sufficient (43).

- **Extracorporeal Shock Wave Lithotripsy**

  Antimicrobial prophylaxis is not recommended as a standard application in extracorporeal shock wave lithotripsy (35). However, it is indicated to use prophylaxis for the control of bacteriuria and in elevated bacterial load, such as permanent catheter, nephrostomy tube, or presence of infective stones (44).

- **Laparoscopic Surgery**

  Although there are not an adequate number of studies on antimicrobial prophylaxis in laparoscopic surgery, it seems reasonable to follow the recommendations provided for open surgical interventions (34).

- **Nephrectomy, Adrenalectomy**

  Although antimicrobial prophylaxis is not recommended as standard, it has been reported that in some cases, its use can be assessed at the discretion of the surgeon (45).

- **Prostatectomy**

  Antimicrobial prophylaxis is recommended in open enucleation of prostate adenoma due to the high risk of postoperative
infection (46). It has been reported that since there is no clear data concerning antimicrobial prophylaxis in radical prostatectomy, this application should be undertaken at the discretion of the surgeon (34).

- **Cystectomy + Ileal Conduit**

The evidence obtained is mostly based on colorectal surgery, and there is only limited data on surgical interventions in urology (19,47). It is recommended to use prophylactic antibiotics as a single dose or for the first 12 hours, however, antimicrobial therapy may be continued up to 72 hours in the presence of factors, such as prolonged surgery or comorbid risk status (34). Antibiotic agents selective to aerobic and anaerobic pathogens should be used.

- **Prosthetic Implantation: Testis, Penile Prosthesis and Artificial Sphincter**

Infectious complications in implant surgery are usually problematic and cause the removal of the prosthesis (48); thus, antimicrobial prophylaxis is recommended (34).

**Conclusion**

Since SSIs are healthcare-related infections, it is important to effectively prevent patients from contracting them. The number of applications for the protection against SSIs is increasing, which in turn raises the demand for interventions based on evidence. Therefore, there is a need to revise the previously published guidelines. New and updated recommendations will be a guide for not only healthcare professionals, but also for professional associations and organizations. These revisions can also be used to develop more detailed implementation guidelines based on previous documents and identify future research priorities. The unresolved issues mentioned in the revised guidelines refer to important points that need to be investigated in the future. For this reason, there is a need for further well-designed studies.

**Ethics**

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**


**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**


